Clinical trials: Neoplasms, Germ Cell and Embryonal
Pheochromocytoma, Paraganglioma
A Study on the Safety and Effectiveness of Temozolomide for Neoadjuvant Treatment of PPGL
This phase II trial studies the effectiveness oftemozolomide in the neoadjuvant therapy oflocally advanced,or unresectable pheochromocytoma or paragangliom(PPGL).
- Trial name
- NCT05885386
- Testing
- Temozolomide
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Peking Union Medical College Hospital
Glioblastoma
Supramarginal Resection in Glioblastoma
Gliomas are the most common malignant brain tumor. Glioblastoma, WHO grade IV astrocytoma, is the most common subtype and unfortunately also the most aggressive subtype with median survival in population based cohorts being only…
- Trial name
- NCT04243005
- Testing
- Supramarginal resection, Conventional surgery
- Where
- 17 sites in Austria, Denmark and 4 more
- Volunteers
- 90 people
- Sponsor
- St. Olavs Hospital
Recurrent High-grade Glioma
A Study of Anlotinib in the Treatment of Recurrent High-grade Glioma
This is a phase II, open-label, single center study, aiming to investigate safety and efficacy of anlotinib in treatment of recurrent high-grade glioma.
- Trial name
- NCT04822805
- Testing
- Anlotinib hydrochloride
- Where
- China
- Volunteers
- 27 people
- Sponsor
- First People's Hospital of Hangzhou
Multiple Myeloma, Lymphoma, Large B-Cell, Diffuse
Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma
The main purpose of this first in human study with CC-122 is to assess the safety and action of a new class of experimental drug (Pleiotropic Pathway Modulator) in patients with advanced tumors unresponsive to standard therapies…
- Conditions
- Multiple Myeloma, Lymphoma, Large B-Cell, Diffuse, Pleiotropic Pathway Modifier, Glioblastoma
- Trial name
- NCT01421524
- Testing
- CC-122
- Where
- 39 sites in United States, Belgium and 3 more
- Volunteers
- 271 people
- Sponsor
- Celgene
Hepatoblastoma, Hepatocellular Carcinoma
Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells
The body has different ways of fighting infection and disease. No single way seems perfect for fighting cancers. This research study combines two different ways of fighting cancer: antibodies and T cells.
- Conditions
- Hepatoblastoma, Hepatocellular Carcinoma, Wilms Tumor, Malignant Rhabdoid Tumor
- Trial name
- NCT06198296
- Testing
- 21.15.GPC3-CAR T cells
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Baylor College of Medicine
High Grade Glioma, Brain Cancer
Efficacy of Nivolumab for Recurrent IDH Mutated High-Grade Gliomas
Immune checkpoint blockade therapies targeting the immunomodulatory effect of cytotoxic T-lymphocyte antigen (CTLA-4) and programmed cell death-1/ Programmed death-ligand 1 (PD-1/PD-L1) have recently demonstrated survival benefit…
- Trial name
- REVOLUMAB (NCT03925246)
- Testing
- Nivolumab
- Where
- 7 sites in France
- Volunteers
- 43 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Melanoma
Study of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-041/KEYNOTE-041)
This study will assess the safety, tolerability, and efficacy of every-3-week dosing (Q3W) of pembrolizumab (MK-3475) in participants with advanced melanoma; participants may receive pembrolizumab for up to 2 years if deriving…
- Trial name
- NCT02180061
- Testing
- Pembrolizumab
- Volunteers
- 42 people
- Sponsor
- Merck Sharp & Dohme LLC
Glioma
Histopathology Images Based Survival Prediction of Glioma Patients Using Artificial Intelligence
This registry aims to collect clinical, molecular and histopathology imaging including detailed survival data, clinical parameters, molecular pathology (1p/19q codeletion, MGMT methylation, IDH and TERTp mutations, etc) and…
- Trial name
- NCT04215224
- Testing
- Histopathology images based survival prediction for glioma patients
- Where
- China
- Volunteers
- 3,500 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Melanoma (Skin)
Biomarkers in Blood Samples From Patients With Stage IV Melanoma Previously Treated With Sargramostim
RATIONALE: Studying samples of blood from patients treated with sargramostim in the laboratory may help doctors learn more about the effects of sargramostim on cells.
- Trial name
- NCT01388569
- Testing
- flow cytometry, immunologic technique, laboratory biomarker analysis
- Volunteers
- 48 people
- Sponsor
- Eastern Cooperative Oncology Group
Medulloblastoma
Hyperfractionated Versus Conventionally Fractionated Radiotherapy in Standard Risk Medulloblastoma (PNET4)
This is an international prospective randomised trial, which will compare two radiotherapy regimens in children and adolescents (aged 4 or 5 years to 21 years inclusive) with carefully staged 'standard risk' medulloblastoma.
- Trial name
- SIOP-PNET-4 (NCT01351870)
- Testing
- Standard Fractionation Regimen, Hyperfractionated Radiotherapy
- Where
- France
- Volunteers
- 52 people
- Sponsor
- Institut Curie
Mixed Gliomas
Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Mixed Gliomas
RATIONALE: Current therapies for adults with recurrent or refractory mixed gliomas provide very limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the…
- Trial name
- NCT00003473
- Testing
- Atengenal, Astugenal
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Burzynski Research Institute
Kidney Cancer, Melanoma (Skin)
Cryoablation or External-Beam Radiation Therapy in Treating Patients With Painful Bone Metastases
RATIONALE: Cryoablation kills cancer cells by freezing them. Radiation therapy uses high-energy x-rays and other types of radiation to kill tumor cells.
- Conditions
- Kidney Cancer, Melanoma (Skin), Metastatic Cancer, Pain
- Trial name
- NCT00540969
- Testing
- cryosurgery, radiation therapy
- Where
- 7 sites in United States
- Volunteers
- 3 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Neuroendocrine Tumor
DIVIT Study Diet and Vitamin Supplementation in Patients With a Neuroendocrine Tumor
This study aims to investigate if the proportion of neuroendocrine tumor (NET) patients with normal vitamin values can be increased, with vitamin suppletion and a personalized diet, Effects of the intervention will be evaluated…
- Trial name
- NCT03143946
- Testing
- Vitamin supplement;, Diet advice
- Where
- Netherlands
- Volunteers
- 53 people
- Sponsor
- University Medical Center Groningen
Glioblastoma Multiforme
TTFields Together With Temozolomide and Radiotherapy in Patients With Newly Diagnosed GBM
The study is a prospective, single arm open label study, designed to test the to evaluate the tolerability and safety outcome of newly diagnosed GBM patients treated with NovoTTF-200A concomitant to Radiotherapy/Temozolomide…
- Trial name
- NCT03780569
- Testing
- NovoTTF-200A, Radiotherapy, Temozolomide
- Where
- Israel
- Volunteers
- 10 people
- Sponsor
- NovoCure Ltd.
Glioblastoma
Comparison of Two Dosing Regimens of Temozolomide in Patients With Progressive or Recurrent Glioblastoma
For patients with progressive or recurrent glioblastoma there is no standard therapy. One strategy is re-exposure to temozolomide in a higher dose. This increase in dosing can be done by 2 regimens.
- Trial name
- DIRECTOR (NCT00941460)
- Testing
- Temozolomide in both arms
- Where
- 16 sites in Austria, Germany and 1 more
- Volunteers
- 105 people
- Sponsor
- Prof. Dr. Wolfgang Wick
Neuroendocrine Tumor
Retrospective Analysis of Patients Re-treated With Lutetium-177 DOTATATE (Lutathera®)
This was a retrospective non-interventional study evaluating the medical records of patients with neuroendocrine tumor (NET) re-treated with lutetium-177 DOTATATE at a single United States institution - the Excel Diagnostics \&…
- Trial name
- NCT05816720
- Testing
- Lutetium-177 DOTATATE
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Novartis Pharmaceuticals
Pheochromocytoma, Non-Secretory Adrenal Adenoma
Intraoperative Hemodynamic Instability During Unilateral Adrenalectomy for Pheochromocytoma
Pheochromocytomas are tumors of the adrenal gland that develop from cells producing adrenaline and noradrenaline. Consequently, intraoperative blood pressure variations (hypertensive and hypotensive episodes) are characteristic…
- Trial name
- HEMODADRE (NCT06062082)
- Testing
- adrenalectomy
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Central Hospital, Nancy, France
Glioma, Patient Reported Outcome Measures
Validity and Reliability Evaluation of the PRO-CTCAE for Adult-type Diffuse Gliomas Patients in Chinese Population
Given the increasing importance of patient's perspective in adverse events reporting, Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE™) has been proposed as new PRO measures in…
- Conditions
- Glioma, Patient Reported Outcome Measures, Self Report, Adverse Effects
- Trial name
- VERONICA (NCT05486923)
- Where
- 14 sites in China
- Volunteers
- 450 people
- Sponsor
- Huashan Hospital
Neuroblastoma
The Role of Aromatic Hydrocarbon Receptor in the Tumorigenesis of Neuroblastoma and Its Relationship With MYCN Expression
Neuroblastoma (NB) is the most common malignant tumor of infancy. Approximately 60% of NB patients are clinically diagnosed as the stage IV disease and have a very poor prognosis with the 5-year survival rate no more than 30%.
- Trial name
- NCT01075360
- Sponsor
- National Taiwan University Hospital
Glioblastoma
Temozolomide vs. Temozolomide and Thalidomide Treatment in Recurrent Glioblastoma
The aim of this study is to evaluate the efficacy and safety of intensive dose temozolomide treatment alone in parallel to a combination with thalidomide in patients with recurrent glioblastoma after standard therapy.
- Trial name
- NCT00521482
- Testing
- Temozolomide, Temozolomide plus Thalidomide
- Where
- Switzerland
- Volunteers
- 40 people
- Sponsor
- University of Zurich
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.